Biotech
Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.
Oral macrocycle drugs
Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.
Epigenetic editing
nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.
Biotechnology
Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.
Biotech
Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.
Synthetic biology
GC Therapeutics (GCTx) develops off-the-shelf iPSC-based cell therapy products for gastrointestinal, neurological, and immunological diseases using their innovative TFome platform.
Medical Device Development
Supira Medical, Inc. is developing the Supira System, a percutaneous ventricular assist device (pVAD) designed to provide hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients.
Biotech
Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.
Biotechnology
Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.
Precision Oncology
FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.
Biotechnology
Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.